Plain-English translation of NCT06492408 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating hepatocellular carcinoma (a type of liver cancer) by injecting ipilimumab and pembrolizumab or durvalumab—powerful immune-boosting medications—directly into the tumor before surgery. Rather than giving these medications through the bloodstream like usual, doctors will inject them straight into the cancer using imaging guidance. The goal is to boost the immune system's ability to fight the cancer while reducing side effects, and to see if this helps shrink tumors and improve survival.
These immune-boosting medications work well for many cancers when given intravenously, but injecting them directly into the tumor may be even more effective by concentrating the medication where it's needed most. This trial will help doctors understand whether this new delivery method is safe and whether it can improve outcomes for people with liver cancer before they have surgery.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive injections of the immune-boosting medication directly into your tumor under imaging guidance—this is done by an interventional radiologist using CT scans to guide the needle. Depending on which study group you are assigned to, you may receive the dual immune medication alone, combined with chemotherapy, or combined with chemotherapy plus another medication called bevacizumab. After the injections, you will have surgery to remove the tumor. You will have regular clinic visits and blood tests to monitor your health and see how well the treatment is working.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment target
~90 participants
Started
July 2024
Primary completion
December 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.